This article is more than 5 years old. Information may no longer be current.

InSite, Nicox enter licensing agreement for AzaSite, AzaSite Xtra and BromSite

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

InSite Vision and Nicox have entered into a licensing agreement for the development and commercialization of InSite’s AzaSite, AzaSite Xtra and BromSite, according to a press release.

Under the agreement, Nicox is granted exclusive rights to commercialize the products in Europe, the Middle East and Africa. InSite will receive an upfront payment of $3 million and potentially $13.75 million in milestone payments, the release said.

Nicox plans to file European Marketing Authorizations for AzaSite and BromSite by the first quarter of 2016, the release said.

AzaSite (1% azithromycin), AzaSite Xtra (2% azithromycin) and BromSite (0.075% bromfenac) are ophthalmic therapeutic products formulated in InSite’s DuraSite drug delivery system.